Hello fellow warriors….well some good news for all of us: I spoke today via video with a doc whose advice I get every 3 months when my CT scans are done, Jonathan Trent MD, Ph.D. (how’s that for qualified??) He runs a clinical trial for CS which has been going for years and gives me [...]
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Vivek Subbiah 1, Robert E Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock PMID: 22914439 PMCID: PMC3496030 DOI: 10.1158/1535-7163.MCT-12-0358 Free PMC article Abstract Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors [...]
New type of immunotherapy may pave the way for better cancer treatments by Karolinska Institutet From left: First author Silke Eisinger and last author Mikael Karlsson from Karolinska Institutet in Sweden. Credit: Mitch Eisinger Immunotherapy for cancer has made great advances and many patients can now receive effective treatments that were not available 10 years [...]
Karina Galoian, Ph.D., is a research associate professor in the Department of Orthopaedics at the University of Miami Leonard M. Miller School of Medicine. She also leads the departmental Institutional Review Board and is Research Director of the Sarcoma Disease Site Group at Sylvester Comprehensive Cancer Center. For the past 10 years, Dr. Galoian has [...]
Last Reminder. We go live at 7:15PM EST (New York time) tonight. We noticed that several of you have tested the connection and are ready to go. If you have any difficulties, Text me at 301-404-7100 We have 109 registrations. Looking forward to your participation. Chondrosarcoma Foundation is inviting you to a scheduled Zoom meeting. [...]
In five days, on November 17, at 7:30pm (Eastern Standard Time / New York), the Chondrosarcoma Foundation will host its first Virtual Dialogue: Straight Talk About Chondrosarcoma. We are fortunate to be bringing together a large diverse group consisting of CS patients and family, oncologists, sarcoma specialists, radiology oncologists, pathologists and CS clinical researchers from [...]
In five days, on November 17, at 7:30pm (Eastern Standard Time / New York), the Chondrosarcoma Foundation will host its first Virtual Dialogue: Straight Talk About Chondrosarcoma. We are fortunate to be bringing together a large diverse group consisting of CS patients and family, oncologists, sarcoma specialists, radiology oncologists, pathologists and CS clinical researchers from [...]
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma William D. Tap, MD1,2; Victor M. Villalobos, MD, PhD3; Gregory M. Cote, MD, PhD4; Howard Burris, MD5; Filip Janku, MD, PhD6; Olivier Mir, MD, MPH, PhD7; Murali Beeram, MD8; Andrew J. Wagner, MD, PhD9; Liewen Jiang, PhD10; [...]
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells Luyuan Li, Ana C. Paz, Breelyn A. Wilky, Britt Johnson, Karina Galoian, Andrew Rosenberg, Guozhi Hu, Gabriel Tinoco, Olaf Bodamer, Jonathan C. Trent Jonathan Trent, M.D., Ph.D. is a world renown leader of [...]